Tango Therapeutics (TNGX) Cash from Operations (2020 - 2026)

Tango Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 44360000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 6.39% year-over-year to 44360000.0; the TTM figure through Mar 2026 stood at 141549000.0 (down 4.59% YoY), while the FY2025 annual figure was 138886000.0, down 5.62% from the prior year.
• Cash from Operations was 44360000.0 for Q1 2026 at Tango Therapeutics, down from 29718000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 19611000.0 in Q3 2022 to a low of 44360000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 31871117.65 across 5 years, with a median of 31135000.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations tumbled 319.5% in 2022, then gained 22.4% in 2023.
• A 5-year view of Cash from Operations shows it stood at 28266000.0 in 2022, then gained by 2.83% to 27467000.0 in 2023, then plunged by 33.42% to 36647000.0 in 2024, then climbed by 18.91% to 29718000.0 in 2025, then slumped by 49.27% to 44360000.0 in 2026.
• The last three Cash from Operations figures came in at 44360000.0 (Q1 2026), 29718000.0 (Q4 2025), and 30952000.0 (Q3 2025), per Business Quant data.